

LifeSci Biotechnology Clinical Trials Index

4/3/2020

Effective at the market close on Monday, April 6, 2020, **FTSV** will be removed from the **LifeSci Biotechnology Clinical Trials Index** and its value will be redistributed to the remaining index components based on their weights.

- On March 2, 2020, Forty Seven agreed to be acquired by Gilead for \$95.50 per share in cash.